Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TEM | Tempus AI, Inc. | 2026-05-22 14:59:44 | 46.2 | -0.29 | -0.63 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TEM | 0001717115 | Tempus AI, Inc. | US88023B1035 | 2549009LA0KWRAGQBX50 | 474903308 | Nasdaq | 7370 | Services-Computer Programming, Data Processing, Etc. | 1231 | NV | 600 WEST CHICAGO AVENUE | CHICAGO | IL | 60654 | UNITED STATES | US | 800-976-5448 | 600 WEST CHICAGO AVENUE, CHICAGO, IL, 60654 | 600 WEST CHICAGO AVENUE, CHICAGO, IL, 60654 | Tempus Labs, Inc. | Health technology | 2015 | Eric Lefkofsky | 2,300 | https://www.tempus.com/ | 11,000,000,000 | — | — | Tempus AI, Inc. (formerly Tempus Labs) is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM." | 2026-05-21 16:04:12 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 11,000,000,000 | 5,600,000,000 | 103.7037 | — | — | — |
| 2024 | 5,400,000,000 | 5,400,000,000 | 100 | — | — | — |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Andrew Polovin | Secretary, Executive Vice President, Chief Legal Officer | 2025 | 610,000 | 0 | 5,698,087 | 274,500 | 0 | 6,582,588 |
| James Rogers | Chief Financial Officer | 2025 | 500,000 | 0 | 5,631,161 | 225,000 | 0 | 6,356,161 |
| Ryan Fukushima | Chief Executive Officer | 2025 | 422,743 | 55,728 | 10,654,002 | 450,000 | 19,836 | 11,602,309 |
| Eric Lefkofsky | Founder, Chief Executive Officer, Chairman | 2025 | 783,333 | 0 | 39,992,500 | 720,000 | 0 | 41,495,833 |
| Erik Phelps | Chief Administrative And Legal Officer, Executive Vice President, Assistant Secretary | 2025 | 610,000 | 48,126 | 3,570,486 | 274,500 | 50,645 | 4,553,757 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 3,800 |
| 2024 | 2,400 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Revenue | 1,271,789,000 | 693,398,000 |
| Cost Of Revenue | 386,102,000 | 243,467,000 |
| Gross Profit | 885,687,000 | 449,931,000 |
| Research And Development Expenses | 172,924,000 | 149,325,000 |
| General And Administrative Expenses | 731,738,000 | 755,351,000 |
| Operating Expenses | 1,524,661,000 | 1,384,480,000 |
| Operating Income | -252,872,000 | -691,082,000 |
| Net Income | -245,028,000 | -705,809,000 |
| Earnings Per Share Basic | -1.41 | -6.23 |
| Earnings Per Share Diluted | -1.41 | -6.23 |
| Weighted Average Shares Outstanding Basic | 174,264 | 119,849 |
| Weighted Average Shares Outstanding Diluted | 174,264 | 119,849 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Cash And Cash Equivalents | 604,787,000 | 340,954,000 |
| Marketable Securities Current | — | — |
| Accounts Receivable | 311,170,000 | 154,819,000 |
| Inventories | 51,724,000 | 38,386,000 |
| Non Trade Receivables | 8,785,000 | 4,300,000 |
| Other Assets Current | 40,498,000 | 26,135,000 |
| Total Assets Current | 1,167,175,000 | 667,603,000 |
| Marketable Securities Non Current | — | — |
| Property Plant And Equipment | 89,156,000 | 58,056,000 |
| Other Assets Non Current | 19,000 | 19,000 |
| Total Assets Non Current | 16,200,000 | 258,513,000 |
| Total Assets | 2,274,838,000 | 926,116,000 |
| Accounts Payable | 81,994,000 | 53,804,000 |
| Deferred Revenue | 92,673,000 | 75,981,000 |
| Short Term Debt | — | — |
| Other Liabilities Current | 8,680,000 | 6,964,000 |
| Total Liabilities Current | 372,388,000 | 291,070,000 |
| Long Term Debt | 208,672,000 | 168,192,000 |
| Other Liabilities Non Current | 56,600,000 | 15,980,000 |
| Total Liabilities Non Current | 1,411,124,000 | 578,707,000 |
| Total Liabilities | 1,783,512,000 | 869,777,000 |
| Common Stock | 17,000 | 16,000 |
| Retained Earnings | -2,395,862,000 | -2,150,834,000 |
| Accumulated Other Comprehensive Income | 902,000 | 94,000 |
| Total Shareholders Equity | 491,326,000 | 56,339,000 |
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Depreciation And Amortization | 32,054,000 | 26,356,000 |
| Share Based Compensation Expense | 124,747,000 | 534,138,000 |
| Other Non Cash Income Expense | -415,000 | — |
| Change In Accounts Receivable | 90,402,000 | 61,037,000 |
| Change In Inventories | 3,369,000 | 9,541,000 |
| Change In Non Trade Receivables | 25,000,000 | — |
| Change In Other Assets | 1,699,000 | 13,683,000 |
| Change In Accounts Payable | -7,241,000 | -23,852,000 |
| Change In Other Liabilities | — | — |
| Cash From Operating Activities | -218,090,000 | -189,045,000 |
| Purchases Of Marketable Securities | 2,740,000 | 36,183,000 |
| Sales Of Marketable Securities | — | — |
| Acquisition Of Property Plant And Equipment | 21,049,000 | 22,121,000 |
| Acquisition Of Business | 376,666,000 | 0 |
| Other Investing Activities | — | — |
| Cash From Investing Activities | -398,355,000 | -130,392,000 |
| Tax Withholding For Share Based Compensation | 0 | 69,918,000 |
| Payments Of Dividends | 0 | 5,625,000 |
| Issuance Of Common Stock | 1,443,000 | 344,000 |
| Repurchase Of Common Stock | 3,040,000 | — |
| Issuance Of Long Term Debt | 196,000,000 | 0 |
| Repayment Of Long Term Debt | 276,892,000 | — |
| Other Financing Activities | — | — |
| Cash From Financing Activities | 884,123,000 | 494,329,000 |
| Change In Cash | 267,616,000 | 175,228,000 |
| Cash At End Of Period | 604,787,000 | 340,954,000 |
| Income Taxes Paid | 654,000 | 206,000 |
| Interest Paid | 44,031,000 | 28,045,000 |
| Fiscal Year | 2025 |
|---|---|
| Earnings Per Share | -1.41 |
| Price To Earnings Ratio | -41.8794 |
| Earnings Growth Rate | -77.3676 |
| Price Earnings To Growth Ratio | 0.5413 |
| Book Value Per Share | 2,819.4349 |
| Price To Book Ratio | 0.0209 |
| Ebitda | -142,053,000 |
| Enterprise Value | -385,824,710.8 |
| Dividend Yield | 0 |
| Dividend Payout Ratio | 0 |
| Debt To Equity Ratio | 0.4247 |
| Capital Expenditures | 63,154,000 |
| Free Cash Flow | -281,244,000 |
| Return On Equity | -0.4987 |
| One Year Beta | 2.5663 |
| Three Year Beta | 2.6847 |
| Five Year Beta | 2.6847 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Schoenherr Thomas Edward | CEO, Diagnostics | 2026-05-19 | 1,580 | D | 107,029 |
| Rogers James William | Chief Financial Officer | 2026-05-19 | 10,853 | D | 126,395 |
| Fukushima Ryan | CEO, Data | 2026-05-19 | 13,550 | D | 603,558 |
| Polovin Andrew | EVP, Chief Legal Officer | 2026-05-19 | 8,703 | D | 128,215 |
| Bartolucci Ryan M | Chief Accounting Officer | 2026-05-19 | 4,116 | D | 74,041 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Nancy Pelosi | 2025-01-17 | CA11 | Purchase | 2025-01-14 | — | $50,001 - $100,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| VESTOR CAPITAL, LLC | 2026-03-31 | 70,000 | 1,538 | 45.5137 |
| SILVERBACK ASSET MANAGEMENT LLC | 2026-03-31 | 1,614,354 | 35,700 | 45.22 |
| Western Wealth Management, LLC | 2026-03-31 | 20,123 | 445 | 45.2202 |
| Silicon Valley Capital Partners | 2026-03-31 | 5,426 | 120 | 45.2167 |
| H&H International Investment, LLC | 2026-03-31 | 904,400 | 20,000 | 45.22 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2026-03-31 | iShares Russell 1000 Growth ETF | IWF | 395,549 | 17,886,725.78 | 0.016 |
| iSHARES TRUST | 2026-03-31 | iShares Russell 1000 ETF | IWB | 68,432 | 3,094,495.04 | 0.0072 |
| iSHARES TRUST | 2026-03-31 | iShares Future AI & Tech ETF | ARTY | 304,250 | 13,758,185 | 0.6611 |
| HARTFORD SERIES FUND INC | 2026-03-31 | IB | HBMCX | 83,997 | 3,798,344.34 | 0.5828 |
| HARTFORD SERIES FUND INC | 2026-03-31 | IA | HIMCX | 83,997 | 3,798,344.34 | 0.5828 |